Get started Log in

RAC — Racura Oncology Share News

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Market Cap
AU$310.77m
Enterprise Value
AU$276.48m
Revenue
AU$3.42m

Australia's Race Oncology rises on orphan drug status for leukemia product
11/06/2024 02:15
Brief: Race Oncology Announces Appointment Of Brendan Brown As CFO
18/03/2024 01:27
Australia's Race Oncology jumps on positive study results for cancer drug
06/03/2024 24:42
Brief: Race Oncology Posts Total Net Loss For Half-Year Attributable A$5.7 Million
28/02/2024 01:18
Australia's Race Oncology rises on CEO appointment
22/11/2023 03:37
Brief: Race Oncology Says Daniel Tillett Appointed Chief Executive Officer
22/11/2023 01:15
Brief: Race Oncology Seeks Trading Halt
02/11/2023 22:17
Brief: Race Oncology Says Peter Smith To Step Into Role Of Executive Director
22/08/2023 02:38
Brief: Race Oncology Executes Agreement With Ardena
12/07/2023 02:31
Brief: Race Oncology Executes Global License Agreement With City Of Hope
10/07/2023 02:40
Brief: Race Oncology Says Mary Harney Appointed Non-Executive Chair
20/04/2023 02:18
Australia's Race Oncology plunges on chief scientific officer's exit
24/03/2023 03:03
Brief: Race Oncology Ltd Seeks Trading Halt
21/03/2023 23:08
Brief: Race Oncology Executes Contracts To Commence Observational Cardioprotection Breast Cancer Trial
13/03/2023 01:11
Brief: Race Oncology Says Total Net Loss For HY Attributable A$4.4 Million
27/02/2023 05:37
Australia's Race Oncology jumps on approval for breast cancer trial
01/02/2023 02:24
Brief: Race Oncology Gets Human Ethics Approval For Observational Cardioprotection Breast Cancer Trial
01/02/2023 01:24
Brief: Race Oncology Says Damian Clarke-Bruce Appointed Managing Director And CEO
14/12/2022 01:03
Australia's Race Oncology jumps on positive feedback from U.S. FDA
23/11/2022 02:43
Brief: Race Oncology Receives Positive Guidance On Zantrene Via Pre-Ind Meeting With Us FDA
23/11/2022 01:20